Tilray Brands Reports Narrower Q2 Loss Despite Mixed Sales Performance
Tilray (TLRY) narrows Q2 losses to $43.5M with 3% revenue growth driven by cannabis gains, though beverage sales decline 21% amid international expansion strategy.
/ 1662 items
#XY↓
Merck Eyes $28-32 Billion Deal for Cancer Drugmaker Revolution Medicines
Merck negotiates potential acquisition of Revolution Medicines for up to $32B, seeking new cancer treatments as Keytruda patent expiration looms in 2028.
Acrivon Cancer Drugs: Small Trials, Big Risks & Cash Concerns
Acrivon Therapeutics (ACRV) announces clinical trial data for experimental cancer drugs ACR-368 and ACR-2316, but significant challenges remain with limited cash runway and unproven efficacy.
Raymond James Starts Coverage on Evommune with Strong Buy Rating
Raymond James begins coverage of Evommune with a Strong Buy rating and a $40 price target, highlighting key Phase 2 clinical catalysts expected in 2026.
ELVN-001 Shows 69% Response Rate in CML Phase 1b Trial Results
Enliven Therapeutics (ELVN) reports encouraging Phase 1b results for ELVN-001, a new treatment for chronic myeloid leukemia, with strong response rates and excellent safety profile.
MoonLake Gets FDA Green Light for HS Treatment Approval Path
MoonLake Immunotherapeutics receives positive FDA feedback, clearing pathway to submit drug application for hidradenitis suppurativa treatment without additional trials needed.